Artesunate is an antimalarial medication used to treat severe malaria infections. There is limited information available on the safety of using artesunate during pregnancy. According to Drug Patent Watch [1], artesunate is classified as a pregnancy category C medication, which means that it should only be used if the potential benefits outweigh the potential risks to the fetus. The drug has not been studied in pregnant women, and there is no data available on its safety in pregnant women.

A study published in the Journal of Global Infectious Diseases [2] suggests that artesunate is safe to use during pregnancy, based on a review of available literature. The authors of the study state that artesunate has been used in pregnant women with severe malaria infections, and there have been no reports of adverse effects on the fetus. However, the study also notes that there is a lack of high-quality data on the safety of artesunate in pregnancy, and further research is needed.

The Centers for Disease Control and Prevention (CDC) [3] recommend the use of artesunate for the treatment of severe malaria in pregnant women, as the benefits of treatment outweigh the potential risks. However, the CDC also notes that the safety of artesunate in pregnancy has not been established, and the drug should only be used if the potential benefits outweigh the potential risks.

In conclusion, there is limited information available on the safety of using artesunate during pregnancy. While some studies suggest that the drug is safe to use, there is a lack of high-quality data on its safety in pregnant women. The drug is classified as a pregnancy category C medication, and should only be used if the potential benefits outweigh the potential risks to the fetus. Pregnant women should consult with their healthcare provider before taking artesunate.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/ARTESUNATE
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328128/
[3] https://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html